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ABSTRACT
Pancreatic cancer is one of the deadliest and a highly aggressive cancer. Its incidence and mortality are highest 
in developed countries. However, in Asia-Pacific region, the incidence and mortality rate of pancreatic cancer 
are also on increasing trend nowadays. Pancreatic cancer incidence rates increase with older age, the highest 
in the 7th and 8th decades. Clinical presentation of pancreatic cancer are usually non-specific, largely dependent 
on tumour size and location, with most patients experience symptoms already late in the disease. Computed 
tomography is considered the method of choice for diagnosis and staging of pancreatic cancer. Management for 
pancreatic cancer include surgical resection, radiotherapy, chemotherapy. Only surgical resection considered 
the potentially curative treatment for pancreatic cancer. Unfortunately, a lot of patients present with disease that 
is not surgically resectable. Prognosis for pancreatic cancer is very poor, despite surgery in resectable patients. 
The overall five-year survival rate is about less than 5%
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ABSTRAK
Kanker pankreas merupakan salah satu tipe kanker yang mematikan dan sangat agresif. Insidens dan 
mortalitas dari kanker pankreas tertinggi adalah dari negara maju. Akan tetapi, di wilayah Asia Pasifik, angka 
insidens dan mortalitas dari kanker pankreas juga dalam tren meningkat sekarang ini. Insiden kanker pankreas 
meningkat dengan bertambah tuanya umur, paling tinggi di dekade ke 7 dan 8. Presentasi klinis dari kanker 
pankreas biasanya non spesifik, tergantung dari ukuran dan lokasi tumor, dengan kebanyakan pasien mengalami 
gejala sudah di stadium lanjut. Computed tomography dianggap metode pilihan untuk mendiagnosis dan 
menentukan stadium dari kanker pankreas. Pengobatan kanker pankreas mencakup bedah reseksi, radioterapi 
dan kemoterapi. Hanya tindakan bedah reseksi yang dianggap berpotensial untuk menyembuhkan kanker 
pankreas. Sayangnya, kebanyakan pasien datang dengan penyakit kanker pankreas yang sudah tidak bisa 
direseksi. Prognosis dari kanker pankreas sangat jelek, meskipun pasien dengan kanker pankreas yang bisa 
direseksi. Angka harapan hidup 5 tahun hanya kurang dari 5%.
Kata kunci: pancreatic cancer, diagnosis, management
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INTRODUCTION
According to GLOBOCAN 2012, pancreatic cancer 
causing more than 331,000 deaths per year, which 
ranked as seventh leading cause of cancer death in 
both sexes together. Pancreatic cancer also ranked the 
12th most common cancer in the world with 338,000 
new cases. The highest incidence and mortality 
rates of pancreatic cancer are found in developed 
countries. In Asia Pacific region, the mortality rate of 
pancreatic cancer are on increasing trend nowadays.2 
The incidence rates of pancreatic cancer for both sexes 
increase with age, the highest in the 7th and 8th decades 
of life. There are many condition that considered as 
risk factors for pancreatic cancer. The risk factors 
are divided into modifiable and non-modifiable. 
Modifiable risk factors include smoking, obesity, 
alcohol and dietary factors, while non-modifiable 
risk factors include increasing age, familial cancer 
syndromes, race, hereditary, diabetes mellitus, and 
chronic pancreatitis.3 
The survival rate of pancreatic cancer is very poor; 
the overall 5-year survival is about less than 5%. Surgical 
resection is the only potentially curative treatment of 
choice for pancreatic cancer. The majority of patients 
are diagnosed at an advanced stage where surgical 
resection is not an option for treatment, hence the low 
survival rate. Despite improvements in imaging, surgical 
techniques and chemotherapy, overall survival has not 
improved in the past few decades.1
Clinical Presentation
The clinical presentation of patients with pancreatic 
cancer are usually non-specific, it largely depends on the 
size and location of the tumor. Pancreatic cancer location 
approximately 60-70% in the head of pancreas, 20-25% 
in the body and tail of pancreas, dan the remaining 
10-20% diffusely involve the pancreas. Symptoms of 
pancreatic cancer include jaundice, abdominal pain, 
weight loss, steatorrhoea, and new onset diabetes.4
Diagnostics
Pancreas protocol CT is the gold standard for 
diagnosis and staging pancreatic cancer. The pancreatic 
protocol CT consists of dual-phase scanning using 
intravenous and oral contrast agents. It is the most 
widely used modality for diagno sis and staging of 
pancreatic cancer due to the fairly wide availability. CT 
can be used to assess po tential vascular involvement 
and meta stases.5,6 Although the widely used of CT for 
diagnosis of pancreatic cancer, MRI can also play an 
important role. MRI have more superior soft tissue 
contrast that can detect small, non-countour deforming 
tumors which may not be seen on CT. MRI and CT have 
similar performance for staging of pancreatic cancer. 
In some cases, MRI improves detection of hepatic 
metastases and characterization of CT-indeterminate 
liver lesions.7 
Another modality used in the diagnosis of pancreatic 
cancer is endoscopic ultrasound (EUS). EUS with 
Fine Neddle Aspiration (FNA) can help secure tissue 
for cytologic diagnosis which made it essential for 
diagnosing pancreatic cancer. EUS can provide 
staging of suspected or proven pancreatic cancer, 
and cytological/histological proof of unresectable 
pancreatic cancer.8 Although EUS is a minimally 
invasive procedure, it is considered a safe procedure 
with low complication rates. Complications of EUS 
procedure include bleeding, pancreatitis, perforation, 
and rarely tumor seeding after EUS-FNA.9
Staging
The American Joint Committee on Cancer (AJCC) 
8th edition staging system for pancreatic cancer is 
shown Table 1. This new staging system different from 
the previous 7th edition. The T category is revised from 
descriptive to size-based definitions. Another change, 
resectability is removed from the T4 category because 
the definition of resectability is not consistent among 
institutions and evolves with advances in surgical 
technique.10
Table 1. American Joint Committee on Cancer (AJCC) 8th edition 
staging system for pancreatic cancer
Tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ (includes PanIN 
III)
T1 Maximum tumor diameter ≤ 2 cm   
T2 Maximum tumor diameter >2, ≤4 cm   
T3 Maximum tumor diameter >4 cm   
T4 Tumor involves the celiac axis, 
common hepatic artery or the 
superior mesenteric artery
  
Lymph node metastases (N)
N0 No regional lymph node metastasis   
N1 Metastasis in 1–3 regional lymph 
nodes
  
N2 Metastasis in ≥ 4 regional lymph 
nodes
Distant metastases (M)
M0 No distant metastasis   
M1 Distant metastasis   
American Joint Comittee on Cancer (AJCC) staging
Stage IA T1 N0 M0
Stage IB T2 N0 M0
Stage IIA T3 N0 M0
Stage IIB T1-3 N1 M0
Stage III Any T N2 M0
T4 Any N M0
Stage IV Any T Any N M1
Reprinted from American Joint Committee on Cancer (AJCC) 8th edition
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy46
Felix Aloysius Budimutiar, Marcellus Simadibrata
TREATMENT
Resectable 
Surgical resection is a potentially curative treatment 
for pancreatic cancer, but only 15–20% of patients 
present with a resectable disease.11 Patients who have 
localized disease with no metastases, good performance 
status and no significant comorbidities are a good 
candidate for surgical resection. The classic surgery for 
resection is a pancreaticoduodenectomy, also known 
as Whipple procedure.12 Pancreatic cancer patients 
who undergo surgical resection is recommended to 
be given adjuvant chemotherapy.13 ESPAC-4 trial 
showed that patients with resected pancreatic cancer 
who were given adjuvant combination of gemcitabine 
and capecitabine had improve overall survival 
compared with only gemcitabine (OS: 28 months vs. 
25.5 months; HR for death 0.82; 95% CI 0.68–0.98).14 
There is still no recommendation to giving neoadjuvant 
chemotherapy in resectable pancreatic cancer because 
no significant improvement in overall survival.15 
Borderline Resectable 
Borderline resectable pancreatic cancer have 
a higher risk for positive margin after resection. 
Therefore, neoadjuvant therapy recommended to be 
given before surgical resection of borderline resectable 
pancreatic cancer. A study using FOLFIRINOX 
followed by capecitabine based chemoradiation 
for borderline resectable pancreatic cancer showed 
a successful pancreatectomy (68%) with negative 
margins resection rates (93%).16
Locally Advanced
Patients with locally advanced pancreatic cancer 
who underwent surgical resection usually had a poor 
prognosis due to high rates of margin positivity after 
surgical resection. Systemic chemotherapy is the 
preferred treatment for locally advanced pancreatic 
cancer. A systematic review and meta analysis study 
using FOLFIRINOX as systematic chemotherapy 
showed a median overall survival longer (24.2 months) 
compared to gemcitabine (6-13 months). The study also 
showed about 28% patients were able to underwent 
surgical resection of tumour and 78% of them had 
negative margin resection.17 Chemotherapy in this 
situation is never curative, and its palliative benefit 
must be balanced against its potential toxic side effects. 
Despite treatment, the survival outcomes remain poor.18
Endoscopic Ultrasound (EUS) Interventional 
Therapy
EUS interventional therapy in pancreatic cancer 
management is emerging. Many applications using 
EUS include fiducials placement, brachytherapy, 
fine needle injection (FNI) and radiofrequency 
ablation (RFA). Fiducial are inert radiopaque 
spheres, coils, or cy lindricals that are implanted 
inside or adjacent to the tumor in order to aid 
image-guided radiation therapy (IGRT). EUS-
guided fiducials placement first reported by 
Pishvaian et al in case series of 13 patients where 
technical success achieved in 94% patients.19 
Followed by several case series with technical 
success more than 90%.20-22 
EUS-brachytherapy apply the insertion of 
a radioactive seed (io dine-125, iridium-192, 
and palladium-103) directly into the pancreatic 
tumor. Brachytherapy still need more larger 
studies for evaluation. Studies done showed EUS-
brachytherapy safe, feasible and have benefit in 
pain control.23-25
EUS-FNI apply direct injection of therapeutic 
agents into pancreatic tumors. EUS-FNI is safe and 
feasible, but not yet show long term efficiency.26-27 
EUS-RFA role in management of pancreatic cancer 
had been showed in recent studies. A study by Song et 
al demonstrated safety and feasibility of EUS-RFA in 
patients with unresectable pancreatic cancer. Technical 
success in this study was achieved 100% however 
overall survival can’t be assessed.28 
CONCLUSION 
Pancreatic cancer still considered one of the deadliest 
cancer types. Survival rate of this disease is very poor. 
There are many diagnostics modality for diagnosing 
pancreatic cancer but early diagnosis of pancreatic 
cancer is still difficult. One of the factor is because 
patients only experience symptoms of pancreatic 
cancer late in the course of the disease. Despite 
treatment, pancreatic cancer high aggressiveness 
and resistance to modern chemo-radiotherapy are 
associated with low rates of long-term survival. Studies 
using EUS as interventional therapy showed promising 
results. More larger studies are needed to establish the 
role of these procedures in the treatment of pancreatic 
cancer. There are no screening recommendations for 
pancreatic cancer, so primary prevention is of utmost 
importance. 
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